cbdMD, Inc. (YCBD)
| Market Cap | 8.82M +452.0% |
| Revenue (ttm) | 19.09M -0.7% |
| Net Income | -3.71M |
| EPS | -0.61 |
| Shares Out | 10.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 194,534 |
| Open | 0.8601 |
| Previous Close | 0.8700 |
| Day's Range | 0.8001 - 0.8601 |
| 52-Week Range | 0.4701 - 2.5600 |
| Beta | 2.17 |
| Analysts | Strong Buy |
| Price Target | 2.00 (+138.1%) |
| Earnings Date | May 15, 2026 |
About YCBD
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products in the United States and internationally. The company owns and operates various consumer hemp-based CBD brands. Its cbdMD brand products include oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. It also provides products for dogs and cats, including tinctures, chews, and topicals under the Paw CBD brand name; non-cannabinoid functional ingredients, such as functional mushrooms under the ATRx brand; and he... [Read more]
Financial Performance
In fiscal year 2025, cbdMD's revenue was $19.19 million, a decrease of -1.50% compared to the previous year's $19.48 million. Losses were -$4.38 million, -43.21% less than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for YCBD stock is "Strong Buy" and the 12-month stock price target is $2.0.
News
cbdMD Launches Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in Medicare
Company brings one of the only combined clinical and toxicological safety dataset in the hemp-derived CBD category into a new provider channel as CMS activates cannabinoid access within value-based ca...
cbdMD Transcript: AGM 2026
The meeting saw all director nominees elected and all proposals, including a reverse stock split, preferred stock issuances, and the 2025 Equity Compensation Plan, approved by strong majorities. Voting was conducted online, and results will be filed with the SEC.
cbdMD Earnings Call Transcript: Q1 2026
Sequential revenue growth continued with Q1 FY26 up 12% from Q4, driven by D2C and wholesale channels. Gross margin declined to 60% due to mix shift, but net loss improved significantly. Acquisition of Bluebird Botanicals and strengthened liquidity position support future growth.
cbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026
CHARLOTTE, N.C., Feb. 17, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD bran...
cbdMD, Inc. to Host Conference Call to Discuss December 31, 2025 First Quarter Results
CHARLOTTE, N.C., Feb. 12, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a c...
cbdMD's Herbal Oasis Expands into Louisiana with Morales Beverage Group Following Strong Texas Momentum
CHARLOTTE, N.C., Feb. 2, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), a leading innovator in wellness and hemp-derived consumer products, today announced a major distribution expansion for ...
cbdMD Strengthens Regulatory Science Platform to Support Emerging Regulatory Cannabinoid Evaluation Pathways
CHARLOTTE, N.C., Jan. 29, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), a leading innovator in hemp-derived wellness products, today announced a strategic initiative to integrate and expand ...
cbdMD Announces Strategic Acquisition of Bluebird Botanicals
CHARLOTTE, N.C., Jan. 14, 2026 /PRNewswire/ -- cbdMD, Inc (NYSE American: YCBD), a leading innovator in hemp-derived wellness products, announced today the closing of the acquisition of substantially ...
cbdMD Earnings Call Transcript: Q4 2025
Fiscal 2025 saw improved operating results, stronger balance sheet, and margin gains, with Oasis beverage expansion and regulatory shifts offering growth potential. Regulatory changes, including a White House executive order, may drive significant new demand in 2026.
cbdMD Reports Third Consecutive Year of Operating Improvement, Strengthens Balance Sheet, and Regains NYSE American Continued Listing Compliance
CHARLOTTE, N.C. , Dec. 19, 2025 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD bra...
cbdMD closes $2.25M Series C convertible preferred stock private placement
cbdMD (YCBD) announced that it has entered into securities purchase agreements with institutional investors whereby company issued the investors an aggregate of 1M shares of Series C convertible prefe...
cbdMD, Inc. Announces Closing of $2.25 Million Series C Preferred Stock Private Placement
CHARLOTTE, N.C. , Dec. 19, 2025 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), a leading wellness company and the parent of Herbal Oasis THC seltzers, ATRx functional mushroom supplements, and Paw...
cbdMD trading halted, news pending
14:05 EST cbdMD (YCBD) trading halted, news pending
cbdMD, Inc. to Host Conference Call to Discuss September 30, 2025, Fourth Quarter and Fiscal Year 2025 Results
CHARLOTTE, N.C. , Dec. 17, 2025 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a ...
Why Is CbdMD Stock (YCBD) Up Again Today?
CbdMD stock was up again on Wednesday alongside speculation about a marijuana executive order.
Here’s Why CbdMD Stock (YCBD) Rocketed Today
CbdMD stock was on the rise Friday alongside reports of incoming cannabis regulation changes.
cbdMD regains compliance with NYSE American listing standards
cbdMD (YCBD) regained full compliance with the continued listing standards of the NYSE American. As a result, the “.BC” indicator has been removed from the list of noncompliant issuers effective
cbdMD, Inc. Regains Compliance with NYSE American Listing Standards
CHARLOTTE, N.C. , Dec. 8, 2025 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), a leading innovator in wellness and hemp-derived products, is pleased to announce that it has regained full compliance...
cbdMD sees Q4 revenue $4.7M-$4.9M vs. $4.6M last year
08:31 EST cbdMD (YCBD) sees Q4 revenue $4.7M-$4.9M vs. $4.6M last year
cbdMD sees FY25 revenue $19.1M-$19.3M vs. $19.5M last year
Net Loss for fiscal 2025 is expected to improve from ($3.7M) to a range of between($1.9M)-($2.1M). “Over the past year, cbdMD (YCBD) has taken decisive action to strengthen the business,
cbdMD Reports Preliminary Unaudited Fourth Quarter and Fiscal 2025 Results
Year Over Year Net Sales Expected to Remain in line with Prior Year Year Over Year Quarterly Net Sales Expected to Increase Between 3% and 5% CHARLOTTE, N.C. , Nov. 21, 2025 /PRNewswire/ -- cbdMD, Inc...
cbdMD's Herbal Oasis Hemp-Derived THC-Infused Social Seltzer Brand Expands its Product Offerings
CHARLOTTE, NC / ACCESS Newswire / October 22, 2025 / cbdMD, Inc. (NYSE American:YCBD), one of the most trusted and recognized cannabidiol (CBD) brands in the United States with a comprehensive line of...
cbdMD’s Herbal Oasis enters distribution partnership with Bevtalk
cbdMD (YCBD) announced that its Herbal Oasis hemp-derived THC-infused social seltzer has expanded distribution throughout most of Florida through a new partnership with Bevtalk Distribution. Bevtalk w...
cbdMD's Herbal Oasis Expands its Florida Footprint with Bevtalk Distribution Partnership
CHARLOTTE, N.C. , Oct. 9, 2025 /PRNewswire/ -- cbdMD , Inc. (NYSE American: YCBD), one of the most trusted and recognized cannabidiol (CBD) brands in the United States with a comprehensive line of dom...